Cogent Biosciences/$COGT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Ticker

$COGT
Sector
Primary listing

Employees

205

COGT Metrics

BasicAdvanced
$2.2B
-
-$2.52
0.36
-

What the Analysts think about COGT

Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.

Bulls say / Bears say

In July 2025, Cogent's SUMMIT trial showed bezuclastinib delivered an 8.91-point placebo-adjusted reduction in symptom score at 24 weeks and 87.4% of patients achieved ≥50% serum tryptase reduction, meeting all primary and key secondary endpoints (Investing.com)
Cogent secured a $400 million non-dilutive debt facility with SLR Capital Partners in June 2025, with $50 million drawn at closing and additional tranches tied to key clinical and commercial milestones, bolstering its financial runway into 2026 (BioSpace)
On July 18, 2025, Citi increased its price target for COGT to $22, citing strong SUMMIT data and projecting up to 52% upside, reflecting growing analyst confidence in bezuclastinib’s commercial potential (Investing.com)
Cogent reported a Q2 2025 net loss of $73.5 million, up from $59.0 million year-over-year, primarily driven by increased R&D expenses, highlighting significant cash burn ahead of commercialization (GuruFocus)
The company’s reliance on milestone-based debt financing underscores cash dependency on successful trial outcomes, with only $50 million drawn from its $400 million facility to date and future tranches contingent on SUMMIT and PEAK readouts (BioSpace)
Cogent raised $150 million through an underwritten stock offering in July 2025, potentially diluting existing shareholders ahead of any revenue generation from bezuclastinib (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

COGT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

COGT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COGT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs